X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Anne McDonald Pritchett, PhD

Anne McDonald Pritchett, PhD Anne McDonald Pritchett, Ph.D., is Senior Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing the development of legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, and other issue areas impacting the environment for innovation. In addition to her public policy work, she and her team lead the development of a range of educational and other materials focused on explaining the R&D process, the value of innovation, and the role and contributions of the innovative biopharmaceutical industry.

Recent Posts

Report: Corporate venture capital is catalyzing groundbreaking biomedical innovation in the United States

By Anne McDonald Pritchett, PhD  |    October 10, 2018
Venture capital is increasingly becoming the growing force for financing biotech and other startups, fueling medical advances in the U.S.  A new report released today from TEConomy, examines the...   Read More

PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis

By Anne McDonald Pritchett, PhD  |    August 2, 2017
Just about every day, I read a news story about the opioid crisis or talk to someone who has been personally impacted by addiction. According to the CDC, opioids, including prescription opioids...   Read More

A critical opportunity to prevent prescription drug abuse

By Anne McDonald Pritchett, PhD  |    June 2, 2017
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently cited addressing the opioid crisis as his highest priority. As someone who has spent the bulk of my career focused on...   Read More

Rare Disease Day: Accelerating innovation for patients in need

By Anne McDonald Pritchett, PhD  |    February 28, 2017
As we celebrate Rare Disease Day, it is important to not only reflect on how far we have come in tackling these devastating and complex conditions, but how much unmet medical remains. While more...   Read More

Seizing the opportunity to rebuild U.S. leadership in STEM

By Anne McDonald Pritchett, PhD  |    June 17, 2016
The United States is not only falling behind other countries on many key science, technology, engineering and mathematics (STEM) indicators, but our public investment in STEM education has...   Read More

Stopping opioid abuse

By Anne McDonald Pritchett, PhD  |    May 6, 2016
According to the U.S. Centers for Disease Control and Prevention (CDC), more than 14,000 people died from overdoses involving opioids in 2014—a four-fold increase since 2009. The agency has...   Read More

New Report: Innovation in the Biopharmaceutical R&D Process – Adapting to a Changing Environment

By Anne McDonald Pritchett, PhD  |    June 30, 2015
With the average cost of developing, testing and receiving approval for a new medicine at $2.6 billion and rising, biopharmaceutical companies are continuously looking at new ways to increase...   Read More

Upcoming Forum on Improving Critical Tools for Preventing Prescription Drug Abuse

By Anne McDonald Pritchett, PhD  |    June 1, 2015
On June 2, the Network for Excellence in Health Innovation (NEHI) will bring experts from across the country to Boston to discuss a critical public health challenge—the abuse of prescription...   Read More

Earth Day 2015: Green Initiatives are Good for Business and the Environment

By Anne McDonald Pritchett, PhD  |    April 22, 2015
Earth Day provides us all with an opportunity to consider the role each of us can play in protecting the Earth’s natural resources. The nation’s innovative biopharmaceutical companies spend...   Read More

Maintaining Appropriate Incentives for Biopharmaceutical Innovation

By Anne McDonald Pritchett, PhD  |    February 4, 2015
As we enter the second half of the decade, the biopharmaceutical industry’s approach to research and development (R&D) continues to evolve to meet the growing demand for new medicines. New...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates